The local release of complexed siRNA from biomaterials opens precisely targeted therapeutic options. In this study, complexed siRNA was loaded to gelatin microparticles cross-linked (cGM) with an anhydride-containing oligomer (oPNMA). We aggregated these siRNA-loaded cGM with human mesenchymal stem cells (hMSC) to microtissues and stimulated them with osteogenic supplements. An efficient knockdown of chordin, a BMP-2 antagonist, caused a remarkably increased alkaline phosphatase (ALP) activity in the microtissues. cGM, as a component of microtissues, mineralized in a differentiation medium within 8–9 days, both in the presence and in the absence of cells. In order to investigate the effects of our pre-differentiated and chordin-silenced microtissues on bone homeostasis, we simulated in vivo conditions in an unstimulated co-culture system of hMSC and human peripheral blood mononuclear cells (hPBMC). We found enhanced ALP activity and osteoprotegerin (OPG) secretion in the model system compared to control microtissues. Our results suggest osteoanabolic effects of pre-differentiated and chordin-silenced microtissues.

Bone regeneration or augmentation is often required prior to or concomitant with implant placement. With the limitations of many existing technologies, a biologically compatible synthetic bone grafting substitute that is osteogenic, bioerodible, and provides spacing-making functionality while acting as a drug delivery vehicle for bioactive molecules could provide an alternative to ‘gold standard’ techniques. In the first part of this work, calcium sulfate (CS) space-making synthetic bone grafts with uniformly embedded poly(β-amino ester) (PBAE) biodegradable hydrogel particles was developed to allow controlled release of bioactive agents. The embedded gel particles’ influence on the physical and chemical characteristics of CS was tested. Namely, the compressive strength and modulus, dissolution, and morphology, were studied. All CS samples dissolved via zero-order surface erosion consistent to one another. Compression testing concluded that the amount, but not size, of embedded gel particles significantly decreased (up to 75%) the overall mechanical strength of the composite. Release studies were conducted to explore this system’s ability to deliver a broad range of drug types and sizes. Lysozyme (model protein for larger growth factors like bone morphogenic protein [BMP]) was loaded into PBAE particles embedded in CS matrix. The release of simvastatin, a small molecule drug capable of up regulating BMP production, was also examined. The release of both lysozyme and simvastatin was governed by dissolution of CS. The second part of this work proposed a bilayered CS implant. The physical and chemical properties were characterized similarly to the CS composites above. Release kinetics of directly loaded simvastatin in either the shell, core, or both were investigated. A sequential release of simvastatin was witnessed giving foresight of the composite’s tunability. The sequential release of an antibacterial, metronidazole, loaded into poly(lactic-co-glycolic acid) (PLGA) particles embedded into the shell along with directly loaded simvastatin either in the shell, core, or both layers was also observed. Through controlled release of bioactive agents, as well as a tunable layered geometry, CS-based implants have the potential to be optimized in order to help streamline the steps required for the healing and regeneration of compromised bone tissue.

Besides osteoconductivity and a high degradation rate, mesoporous bioactive glasses (MBGs) are specific for their highly ordered channel structure and high specific surface area, making them suitable as drug and/or growth factor delivery systems. On the other hand, the mesoporous channel structure and MBG composition can have an effect on common cell evaluation assays, leading to inconclusive results. This effect is especially important when MBG is mixed in composite bioinks, together with cells. Additionally, the hydrogel component of the ink can influence the degradation of MBG, leading to different ion releases, which can additionally affect the analyses. Hence, our aim here was to show how the MBG structure and composition influence common cell viability and differentiation assays when calcium (Ca)- or magnesium (Mg)-containing glass is part of an alginate-based composite bioink. We suggested pre-labeling of cells with DiI prior to bioprinting and staining with calcein-AM to allow identification of metabolically active cells expressing signals in both green and red channels, allowing the use of fluorescence imaging for cell viability evaluations in the presence of high amounts (7 wt %) of MBGs. The release and uptake of ions during degradation of CaMBG and MgMBG were significantly changed by alginate in the composite bioinks, as confirmed by higher release and uptake from bulk glasses. Additionally, we detected a burst release of Mg²⁺ from composites only after 24 h of incubation. Furthermore, we demonstrated that released ions and the mesoporous channel structure affect the measurement of lactate dehydrogenase (LDH) and alkaline phosphatase activity (ALP) in bioprinted composite scaffolds. Measured LDH activity was significantly decreased in the presence of CaMBG. On the other hand, the presence of MgMBG induced increased signal measured for the ALP. Taken together, our findings show how composite bioinks containing MBGs can interfere with common analyses, obtaining misleading results.

Eine bevorzugte Zellquelle für den Einsatz im Tissue Engineering sind mesenchymale Stammzellen (MSZ). Diese besitzen, neben einer hohen Proliferationsrate, die Fähigkeit, sich in verschiedene Zellen des mesodermen Ursprungs und in die entsprechenden Gewebetypen zu entwickeln. Um ein funktionales Gewebe zu erhalten ist es Ziel, sich bereits in vitro den in vivo Bedingungen anzunähern. Hierbei spielen neben der dreidimensionalen Struktur der Scaffolds auch die biochemische Mikroumgebung der Zellen in Form der unlöslichen extrazellulären Matrix (EZM) und den löslichen Mediatorproteinen wie Wachstums- und Differenzierungsfaktoren, sowie die physikalische Stimulation der Zellen eine wichtige Rolle. Während sich gegenwärtige Untersuchungen im TE vorwiegend mit den alleinigen Einflussfaktoren beschäftigen, verfolgt die vorliegende Arbeit das Ziel, die Auswirkungen kombinierter Stimuli durch Verwendung einer artifiziellen EZM, bestehend aus definierten Komponenten der nativen EZM, und physikalischer Stimuli durch elektrische Felder zu untersuchen. Letzteres erfolgte mit einem innerhalb der Arbeitsgruppe neu entwickelten System, dass die Stimulation von Zellen mit ausschließlich elektrischen Feldern, ohne störende Nebeneinflüsse, erlaubt.

No description available.

Eine bevorzugte Zellquelle für den Einsatz im Tissue Engineering sind mesenchymale Stammzellen (MSZ). Diese besitzen, neben einer hohen Proliferationsrate, die Fähigkeit, sich in verschiedene Zellen des mesodermen Ursprungs und in die entsprechenden Gewebetypen zu entwickeln. Um ein funktionales Gewebe zu erhalten ist es Ziel, sich bereits in vitro den in vivo Bedingungen anzunähern. Hierbei spielen neben der dreidimensionalen Struktur der Scaffolds auch die biochemische Mikroumgebung der Zellen in Form der unlöslichen extrazellulären Matrix (EZM) und den löslichen Mediatorproteinen wie Wachstums- und Differenzierungsfaktoren, sowie die physikalische Stimulation der Zellen eine wichtige Rolle. Während sich gegenwärtige Untersuchungen im TE vorwiegend mit den alleinigen Einflussfaktoren beschäftigen, verfolgt die vorliegende Arbeit das Ziel, die Auswirkungen kombinierter Stimuli durch Verwendung einer artifiziellen EZM, bestehend aus definierten Komponenten der nativen EZM, und physikalischer Stimuli durch elektrische Felder zu untersuchen. Letzteres erfolgte mit einem innerhalb der Arbeitsgruppe neu entwickelten System, dass die Stimulation von Zellen mit ausschließlich elektrischen Feldern, ohne störende Nebeneinflüsse, erlaubt.:1 Einleitung und Zielstellung 2 Theoretische Grundlagen 2.1 Der Knochen 2.1.1 Allgemeine Biologie und Physiologie des Knochengewebes 2.1.2 Knochenersatzmaterialien 2.2 Tissue Engineering von Knochengewebe 2.2.1 Trägermaterialien für das TE von Knochen 2.2.2 Zellen für das TE von Knochen 2.2.3 Artifizielle extrazelluläre Matrizes für das TE von Knochen 2.3 Einfluss elektrischer Felder auf Knochenumbauprozesse 2.3.1 Methoden zur Applikation von elektrischen Feldern 2.3.2 In vitro Untersuchungen zum Einfluss elektrischer Felder 2.3.3 Methode der Transformator-ähnlichen Einkopplung (TC) 3 Materialien 3.1 Technische Hilfsmittel und Geräte 3.2 Verbrauchsmaterialien 3.3 Chemikalien, Reagenzien und Kits 3.4 Antikörper 3.5 Oligonukleotide 3.6 Puffer-, Medien- und Lösungszusammensetzungen 3.7 Zellen 4 Methoden 4.1 Polycaprolacton-Co-Lactid (PCL)-Scaffolds 4.1.1 Präparation und Hydrophilisierung der PCL-Scaffolds 4.1.2 Beschichtung der PCL-Scaffolds 4.1.3 Charakterisierung der Beschichtung auf den PCL-Scaffolds 4.2 Zellkulturtechniken 4.2.1 Auftauen und Subkultivierung 4.2.2 Einfrieren 4.2.3 Induktion der osteogenen Differenzierung 4.2.4 Induktion der adipogenen Differenzierung 4.2.5 Induktion der chondrogenen Differenzierung 4.2.6 Besiedlung und Kultivierung der Zell-Matrix-Konstrukte 4.2.7 Elektrische Stimulation der Zell-Matrix-Konstrukte 4.2.8 Blockierung definierter Signaltransduktionswege 4.3 Mikroskopische Analytik der Zellen 4.3.1 Darstellung der Zellverteilung mittels Rasterelektronenmikroskopie (REM) 4.3.2 Qualitative Bestimmung von Fetttröpfchen mittels Oil-Red-O Färbung 4.3.3 Qualitative Bestimmung der Mineralisierung mittels vonKossa- Färbung 4.4 Durchflusszytometrie 4.5 Biochemische Analytik der Zellen 4.5.1 Bestimmung der Zellzahl mittels Lactatdehydrogenase (LDH)- Aktivität 4.5.2 Bestimmung der alkalische Phosphatase (ALP)-Aktivität 4.5.3 Quantitative Bestimmung des Kalziumgehaltes 4.6 Molekularbiologische Analytik / Genexpressionsanalyse 4.6.1 RNA Extraktion 4.6.2 cDNA-Synthese / Reverse Transkriptase PCR (RT-PCR) 4.6.3 Amplifikation von cDNA mittels quantitativer Real-Time PCR (qPCR) 4.7 Statistische Auswertung 5 Weiterentwicklung der Kammer zur TC-Einkopplung 5.1 Grundlegende theoretische Betrachtungen zur TC-Einkopplung 5.1.1 Ersatzschaltbild der TC-Einkopplung 5.1.2 Abschätzung des Eisenkernquerschnitts 5.1.3 Einfluss der Primärwindungszahl 5.2 Neudimensionierung und Aufbau der Stimulationseinrichtung 5.3 Verlauf der elektrischen Größen 5.3.1 Simulation 5.3.2 Messung 5.3.3 Abschätzung des magnetischen Feldes in der Kammer 5.4 Zusammenfassung 6 Zellexperimentelle Ergebnisse 6.1 Charakterisierung der humanen MSZ nach in vitro Kultivierung 6.1.1 Morphologie 6.1.2 Phänotypische Charakterisierung mittels Durchflusszytometrie 6.1.3 Multipotentes Differenzierungspotential 6.2 Zellverhalten auf den unbeschichteten PCL-Scaffolds 6.2.1 Ermittlung eines geeigneten Besiedlungsregimes 6.2.2 Zellverteilung und Proliferation der MSZ 6.2.3 Osteogene Differenzierung der MSZ 6.3 Einfluss der aEZM auf das Zellverhalten von MSZ 6.3.1 Quantitative Bestimmung der aEZM-Komponenten 6.3.2 Einfluss der aEZM auf die Adhärenz und Proliferation von MSZ 6.3.3 Einfluss der aEZM auf die osteogene Differenzierung von MSZ 6.4 Einfluss elektrischer Felder auf das Zellverhalten von MSZ 6.4.1 Einfluss der elektrischen Felder auf die Proliferation und osteogene Differenzierung von MSZ 6.4.2 Einfluss elektrischer Felder in Kombination mit Koll/sHya enthaltenden aEZM auf die Proliferation und osteogene Differenzierung von MSZ 6.4.3 Untersuchungen zu möglichen Signaltransduktionswegen 7 Diskussion der Ergebnisse 7.1 Charakterisierung der humanen MSZ nach in vitro Kultivierung 7.2 Zellverhalten auf den unbeschichteten PCL-Scaffolds 7.3 Einfluss der aEZM auf das Zellverhalten von MSZ 7.4 Einfluss elektrischer Felder auf das Zellverhalten von MSZ 8 Zusammenfassung und Ausblick Literaturverzeichnis Danksagung Eigene Publikationen und Mitautorschaften A Zusatzinformationen für die quantitative RT-PCR A.1 Versuchsdesign der Genexpressionsanalysen A.2 Qualitätskontrolle der isolierten RNA

<div>Delayed fracture healing is a major health issue involved with aging. Therefore, strategies to improve the pace of repair and prevent non-union are needed in order to improve patient outcomes and lower healthcare costs. In order to accelerate bone fracture healing noninvasively, we sought to develop a drug delivery system that could safely and effectively be used to deliver therapeutics to the site of a bone fracture. We elected to pursue the promising strategy of using small-molecule drug conjugates that deliver therapeutics to bone in an attempt to increase the efficacy and safety of drugs for treating bone-related diseases.</div><div>This strategy also opened the door for new methods of administering drugs. Traditionally, administering bone anabolic agents to treat bone fractures has relied entirely on local surgical application. However, because it is so invasive, this method’s use and development has been limited. By conjugating bone anabolic agents to bone-homing molecules, bone fracture treatment can be performed through minimally invasive subcutaneous administration. The exposure of raw hydroxyapatite that occurs with a bone fracture allows these high-affinity molecules to chelate the calcium component of hydroxyapatite and localize primarily to the fracture site.</div><div>Many bone-homing molecules (such as bisphosphonates and tetracycline targeting) have been developed to treat osteoporosis. However, many of these molecules have toxicity associated with them. We have found that short oligopeptides of acidic amino acids can localize to bone fractures with high selectivity and with very low toxicity compared to bisphosphonates and tetracyclines.</div><div>We have also demonstrated that these molecules can be used to target peptides of all chemical classes: hydrophobic, neutral, cationic, anionic, short, and long. This ability is particularly useful because many bone anabolics are peptidic in nature. We have found that acidic oligopeptides have better persistence at the site of the fracture than bisphosphonate-targeted therapeutics. This method allows for a systemic administration of bone anabolics to treat bone fractures, which it achieves by accumulating the bone anabolic at the fracture site. It also opens the door for a new way of treating the prevalent afflictions of broken bones and the deaths associated with them.</div><div>We further developed this technology by using it to deliver anabolic peptides derived from growth factors, angiogenic agents, neuropeptides, and extracellular matrix fragments. We found several promising therapeutics that accelerated the healing of bone fractures by improving the mineralization of the callus and improving the overall strength. We optimized the performance of these molecules by improving their stability, targeting ligands, linkers, dose, and dosing frequency.</div><div>We also found that these therapeutics could be used to accelerate bone fracture repair even in the presence of severe comorbidities (such as diabetes and osteoporosis) that typically slow the repair process. We found that, unlike the currently approved therapeutic for fracture healing (BMP2), our therapeutics improved functionality and reduced pain in addition to strengthening the bone. These optimized targeted bone anabolics were not only effective at healing bone fractures but they also demonstrated that they could be used to speed up spinal fusion. Additionally, we demonstrated that acidic oligopeptides have potential to be used to treat other bone diseases with damaged bone.</div><div>With these targeted therapeutics, we no longer have to limit bone fracture healing to casts or invasive surgeries. Rather, we can apply these promising therapeutics that can be administered non-invasively to augment existing orthopedic practices. As these therapeutics move into clinical development, we anticipate that they will be able to reduce the immobilization time that is the source of so many of the deadly complications associated with bone fracture healing, particularly in the elderly.</div>